Tetracycline-Guided Debridement and Cone Beam Computed Tomography for the Treatment of Bisphosphonate-Related Osteonecrosis of the Jaw: A Technical Note

Treatment strategies and outcomes of bisphosphonate-related osteonecrosis of the jaw (BRONJ) with characterization of patients: a systematic review

“…82,87,149 Fluorescence or tetracycline guided debridement was reported in two publications. 79,99 Seven hundred and fifteen patients were treated by medical and minimally invasive surgical treatment, 422 patients were treated by medical, minimally invasive and major surgical treatment, 286 patients were treated by medical treatment only, 767 patients were treated by minimally invasive surgical treatment, 252 patients were treated by major surgical treatment, 25 patients were treated by guided debridement, 322 patients were treated with laser therapy, 92 patients were treated with growth factors, 161 patients were treated with ozone therapy, 361 patients stopped BP treatment in addition to other treatment modalities, 45 patients were treated with HBO, and 27 patients were treated with teriparatide (Table 4).…”

Treatment perspectives for medication-related osteonecrosis of the jaw (MRONJ)

“…Bone fluorescence can be used to distinguish between viable and necrotic bone (Pautke et al, 2009(Pautke et al, , 2010a(Pautke et al, , 2006Fleisher et al, 2008). For example, tetracycline and its derivatives possess fluorescence properties (Harris, 1960) which, under appropriate excitation light fluoresces green at approximately 525e540 nm (Pautke et al, 2010b).…”

“…Due to its affinity to calcium, tetracycline is incorporated into the bone predominantly in areas of bone remodeling and bone apposition (Rauch et al, 2007). Viable bone is marked by green fluorescence that can be visualized intraoperatively with a VELscope fluorescence lamp (LED Dental, Atlanta, Georgia, USA), a certified medical device approved by the American Dental Association for the detection of mucosal tissue abnormalities (Pautke et al, 2009(Pautke et al, , 2010aFleisher et al, 2008;Assaf et al, 2014). In contrast, necrotic bone shows no or only pale fluorescence.…”

Intraoperative detection of viable bone with fluorescence imaging using Visually Enhanced Lesion Scope in patients with bisphosphonate-related osteonecrosis of the jaw: clinical and pathological evaluation

“…To date, it is not possible to visualize this feature intraoperatively, and no successful surgical treatment protocols have been published. Conversely, tetracycline bone fluorescence has been introduced as the surgical therapy for BRONJ in some hospital facilities [29,30]. The prospective study by Pautke et al (2010) reports that the postoperative mucosal closure rate was 85 %, exposed bone was observed, and BRONJ recurred in 15 % of the lesions.…”